title	geo_accession	status	submission_date	last_update_date	type	channel_count	source_name_ch1	organism_ch1	characteristics_ch1	characteristics_ch1.1	characteristics_ch1.2	characteristics_ch1.3	characteristics_ch1.4	molecule_ch1	extract_protocol_ch1	label_ch1	label_protocol_ch1	taxid_ch1	hyb_protocol	scan_protocol	description	data_processing	platform_id	contact_name	contact_laboratory	contact_department	contact_institute	contact_address	contact_city	contact_state	contact_zip/postal_code	contact_country	supplementary_file	supplementary_file.1	data_row_count
CHD7-1 whole blood CHD7 LOF genomic DNA	GSM2562699	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 4	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-1	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562699/suppl/GSM2562699_9376525031_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562699/suppl/GSM2562699_9376525031_R05C01_Red.idat.gz	485577
CHD7-2 whole blood CHD7 LOF genomic DNA	GSM2562700	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-2	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562700/suppl/GSM2562700_9376525031_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562700/suppl/GSM2562700_9376525031_R01C02_Red.idat.gz	485577
CHD7-3 whole blood CHD7 LOF genomic DNA	GSM2562701	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 14	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-3	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562701/suppl/GSM2562701_9376525009_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562701/suppl/GSM2562701_9376525009_R05C01_Red.idat.gz	485577
CHD7-4 whole blood CHD7 LOF genomic DNA	GSM2562702	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 12.8	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-4	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562702/suppl/GSM2562702_9376525033_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562702/suppl/GSM2562702_9376525033_R02C01_Red.idat.gz	485577
CHD7-5 whole blood CHD7 LOF genomic DNA	GSM2562703	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 18	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-5	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562703/suppl/GSM2562703_9376525033_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562703/suppl/GSM2562703_9376525033_R04C02_Red.idat.gz	485577
CHD7-6 whole blood CHD7 LOF genomic DNA	GSM2562704	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 24	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-6	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562704/suppl/GSM2562704_9376525027_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562704/suppl/GSM2562704_9376525027_R01C01_Red.idat.gz	485577
CHD7-7 whole blood CHD7 LOF genomic DNA	GSM2562705	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 3	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-7	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562705/suppl/GSM2562705_9376525027_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562705/suppl/GSM2562705_9376525027_R03C01_Red.idat.gz	485577
CHD7-8 whole blood CHD7 LOF genomic DNA	GSM2562706	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 6	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-8	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562706/suppl/GSM2562706_9376525027_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562706/suppl/GSM2562706_9376525027_R03C02_Red.idat.gz	485577
CHD7-9 whole blood CHD7 LOF genomic DNA	GSM2562707	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 9	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-9	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562707/suppl/GSM2562707_9376525027_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562707/suppl/GSM2562707_9376525027_R06C02_Red.idat.gz	485577
CHD7-10 whole blood CHD7 LOF genomic DNA	GSM2562708	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 0.02	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-10	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562708/suppl/GSM2562708_9376525052_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562708/suppl/GSM2562708_9376525052_R01C01_Red.idat.gz	485577
CHD7-11 whole blood CHD7 LOF genomic DNA	GSM2562709	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 12	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-11	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562709/suppl/GSM2562709_9376525052_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562709/suppl/GSM2562709_9376525052_R04C01_Red.idat.gz	485577
CHD7-12 whole blood CHD7 LOF genomic DNA	GSM2562710	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 19	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-12	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562710/suppl/GSM2562710_9376525052_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562710/suppl/GSM2562710_9376525052_R06C01_Red.idat.gz	485577
CHD7-13 whole blood CHD7 LOF genomic DNA	GSM2562711	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 19	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-13	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562711/suppl/GSM2562711_9376525052_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562711/suppl/GSM2562711_9376525052_R03C02_Red.idat.gz	485577
CHD7-14 whole blood CHD7 LOF genomic DNA	GSM2562712	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 4	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-14	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562712/suppl/GSM2562712_9376525032_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562712/suppl/GSM2562712_9376525032_R02C02_Red.idat.gz	485577
CHD7-15 whole blood CHD7 LOF genomic DNA	GSM2562713	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 10.8	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-15	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562713/suppl/GSM2562713_9344730057_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562713/suppl/GSM2562713_9344730057_R04C02_Red.idat.gz	485577
CHD7-16 whole blood CHD7 LOF genomic DNA	GSM2562714	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 7	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-16	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562714/suppl/GSM2562714_9376525031_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562714/suppl/GSM2562714_9376525031_R02C01_Red.idat.gz	485577
CHD7-17 whole blood CHD7 LOF genomic DNA	GSM2562715	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 15	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-17	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562715/suppl/GSM2562715_9376525031_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562715/suppl/GSM2562715_9376525031_R04C02_Red.idat.gz	485577
CHD7-18 whole blood CHD7 LOF genomic DNA	GSM2562716	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 10	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-18	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562716/suppl/GSM2562716_9376525033_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562716/suppl/GSM2562716_9376525033_R01C02_Red.idat.gz	485577
CHD7-19 whole blood CHD7 LOF genomic DNA	GSM2562717	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 4	sample type: CHD7 LOF discovery cohort	disease state: CHARGE	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-19	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562717/suppl/GSM2562717_9376525032_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562717/suppl/GSM2562717_9376525032_R03C02_Red.idat.gz	485577
CHD7-20 whole blood CHD7 VUS genomic DNA	GSM2562718	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 5	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-20	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562718/suppl/GSM2562718_9934987063_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562718/suppl/GSM2562718_9934987063_R02C02_Red.idat.gz	485577
CHD7-21 whole blood CHD7 VUS genomic DNA	GSM2562719	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 3	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-21	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562719/suppl/GSM2562719_200325530153_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562719/suppl/GSM2562719_200325530153_R04C02_Red.idat.gz	485577
CHD7-22 whole blood CHD7 VUS genomic DNA	GSM2562720	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 0.01	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-22	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562720/suppl/GSM2562720_9376525031_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562720/suppl/GSM2562720_9376525031_R04C01_Red.idat.gz	485577
CHD7-23 whole blood CHD7 VUS genomic DNA	GSM2562721	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 0.5	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-23	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562721/suppl/GSM2562721_9376525033_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562721/suppl/GSM2562721_9376525033_R05C01_Red.idat.gz	485577
CHD7-24 whole blood CHD7 VUS genomic DNA	GSM2562722	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 2	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-24	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562722/suppl/GSM2562722_9376525032_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562722/suppl/GSM2562722_9376525032_R04C02_Red.idat.gz	485577
CHD7-25 whole blood CHD7 VUS genomic DNA	GSM2562723	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-25	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562723/suppl/GSM2562723_9376525027_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562723/suppl/GSM2562723_9376525027_R02C02_Red.idat.gz	485577
CHD7-26 whole blood CHD7 VUS genomic DNA	GSM2562724	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 4	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-26	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562724/suppl/GSM2562724_9376525009_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562724/suppl/GSM2562724_9376525009_R03C01_Red.idat.gz	485577
CHD7-27 whole blood CHD7 VUS genomic DNA	GSM2562725	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 4	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-27	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562725/suppl/GSM2562725_9376525027_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562725/suppl/GSM2562725_9376525027_R05C02_Red.idat.gz	485577
CHD7-28 whole blood CHD7 VUS genomic DNA	GSM2562726	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-28	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562726/suppl/GSM2562726_9376525052_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562726/suppl/GSM2562726_9376525052_R05C02_Red.idat.gz	485577
CHD7-29 whole blood CHD7 VUS genomic DNA	GSM2562727	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-29	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562727/suppl/GSM2562727_10003885124_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562727/suppl/GSM2562727_10003885124_R06C02_Red.idat.gz	485577
CHD7-30 whole blood CHD7 VUS genomic DNA	GSM2562728	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 0.08	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-30	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562728/suppl/GSM2562728_3999875087_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562728/suppl/GSM2562728_3999875087_R02C02_Red.idat.gz	485577
CHD7-31 whole blood CHD7 VUS genomic DNA	GSM2562729	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 5	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-31	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562729/suppl/GSM2562729_9934987063_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562729/suppl/GSM2562729_9934987063_R05C02_Red.idat.gz	485577
CHD7-32 whole blood CHD7 VUS genomic DNA	GSM2562730	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 9	sample type: CHD7 sequence variant	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-32	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562730/suppl/GSM2562730_200325530153_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562730/suppl/GSM2562730_200325530153_R03C02_Red.idat.gz	485577
CHD7-33 whole blood CHD7 VUS genomic DNA	GSM2562731	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 50	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-33	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562731/suppl/GSM2562731_200069280070_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562731/suppl/GSM2562731_200069280070_R02C01_Red.idat.gz	485577
CHD7-34 whole blood CHD7 pathogenic genomic DNA	GSM2562732	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 2	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-34	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562732/suppl/GSM2562732_200069280070_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562732/suppl/GSM2562732_200069280070_R03C01_Red.idat.gz	485577
CHD7-35 whole blood CHD7 VUS genomic DNA	GSM2562733	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 2	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-35	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562733/suppl/GSM2562733_200069280070_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562733/suppl/GSM2562733_200069280070_R05C01_Red.idat.gz	485577
CHD7-36 whole blood CHD7 pathogenic genomic DNA	GSM2562734	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 24	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-36	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562734/suppl/GSM2562734_200069280070_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562734/suppl/GSM2562734_200069280070_R06C01_Red.idat.gz	485577
CHD7-37 whole blood CHD7 VUS genomic DNA	GSM2562735	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 38	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-37	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562735/suppl/GSM2562735_200069280019_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562735/suppl/GSM2562735_200069280019_R02C02_Red.idat.gz	485577
CHD7-38 whole blood CHD7 VUS genomic DNA	GSM2562736	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 20	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-38	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562736/suppl/GSM2562736_200069280070_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562736/suppl/GSM2562736_200069280070_R01C02_Red.idat.gz	485577
CHD7-39 whole blood CHD7 VUS genomic DNA	GSM2562737	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 19	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-39	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562737/suppl/GSM2562737_200069280070_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562737/suppl/GSM2562737_200069280070_R02C02_Red.idat.gz	485577
CHD7-40 whole blood CHD7 pathogenic genomic DNA	GSM2562738	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-40	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562738/suppl/GSM2562738_200069280070_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562738/suppl/GSM2562738_200069280070_R04C02_Red.idat.gz	485577
CHD7-41 whole blood CHD7 pathogenic genomic DNA	GSM2562739	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 8	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-41	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562739/suppl/GSM2562739_200069280070_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562739/suppl/GSM2562739_200069280070_R06C02_Red.idat.gz	485577
CHD7-42 whole blood CHD7 VUS genomic DNA	GSM2562740	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 3	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-42	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562740/suppl/GSM2562740_200069280030_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562740/suppl/GSM2562740_200069280030_R02C01_Red.idat.gz	485577
CHD7-43 whole blood CHD7 VUS genomic DNA	GSM2562741	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 23	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-43	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562741/suppl/GSM2562741_200069280030_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562741/suppl/GSM2562741_200069280030_R03C01_Red.idat.gz	485577
CHD7-44 whole blood CHD7 VUS genomic DNA	GSM2562742	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 2	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-44	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562742/suppl/GSM2562742_200069280030_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562742/suppl/GSM2562742_200069280030_R05C01_Red.idat.gz	485577
CHD7-45 whole blood CHD7 VUS genomic DNA	GSM2562743	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 35	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-45	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562743/suppl/GSM2562743_200069280030_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562743/suppl/GSM2562743_200069280030_R06C01_Red.idat.gz	485577
CHD7-46 whole blood CHD7 pathogenic genomic DNA	GSM2562744	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 3	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-46	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562744/suppl/GSM2562744_200069280030_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562744/suppl/GSM2562744_200069280030_R01C02_Red.idat.gz	485577
CHD7-47 whole blood CHD7 pathogenic genomic DNA	GSM2562745	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 31	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-47	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562745/suppl/GSM2562745_200069280030_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562745/suppl/GSM2562745_200069280030_R02C02_Red.idat.gz	485577
CHD7-48 whole blood CHD7 VUS genomic DNA	GSM2562746	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 49	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-48	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562746/suppl/GSM2562746_200069280030_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562746/suppl/GSM2562746_200069280030_R04C02_Red.idat.gz	485577
CHD7-49 whole blood CHD7 VUS genomic DNA	GSM2562747	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 8	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-49	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562747/suppl/GSM2562747_200053730139_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562747/suppl/GSM2562747_200053730139_R02C01_Red.idat.gz	485577
CHD7-50 whole blood CHD7 VUS genomic DNA	GSM2562748	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 18	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-50	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562748/suppl/GSM2562748_200053730139_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562748/suppl/GSM2562748_200053730139_R05C01_Red.idat.gz	485577
CHD7-51 whole blood CHD7 pathogenic genomic DNA	GSM2562749	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 2	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-51	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562749/suppl/GSM2562749_200053730139_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562749/suppl/GSM2562749_200053730139_R06C01_Red.idat.gz	485577
CHD7-52 whole blood CHD7 pathogenic genomic DNA	GSM2562750	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 3	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-52	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562750/suppl/GSM2562750_200053730139_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562750/suppl/GSM2562750_200053730139_R01C02_Red.idat.gz	485577
CHD7-53 whole blood CHD7 pathogenic genomic DNA	GSM2562751	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 18	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-53	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562751/suppl/GSM2562751_200053730139_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562751/suppl/GSM2562751_200053730139_R04C02_Red.idat.gz	485577
CHD7-54 whole blood CHD7 VUS genomic DNA	GSM2562752	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 32	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-54	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562752/suppl/GSM2562752_200053730139_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562752/suppl/GSM2562752_200053730139_R05C02_Red.idat.gz	485577
CHD7-55 whole blood CHD7 pathogenic genomic DNA	GSM2562753	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 2	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-55	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562753/suppl/GSM2562753_200069280004_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562753/suppl/GSM2562753_200069280004_R02C01_Red.idat.gz	485577
CHD7-56 whole blood CHD7 pathogenic genomic DNA	GSM2562754	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 17	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-56	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562754/suppl/GSM2562754_200069280004_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562754/suppl/GSM2562754_200069280004_R03C01_Red.idat.gz	485577
CHD7-57 whole blood CHD7 VUS genomic DNA	GSM2562755	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 2	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-57	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562755/suppl/GSM2562755_200069280004_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562755/suppl/GSM2562755_200069280004_R05C01_Red.idat.gz	485577
CHD7-58 whole blood CHD7 pathogenic genomic DNA	GSM2562756	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 22	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-58	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562756/suppl/GSM2562756_200069280004_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562756/suppl/GSM2562756_200069280004_R01C02_Red.idat.gz	485577
CHD7-59 whole blood CHD7 VUS genomic DNA	GSM2562757	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 48	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-59	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562757/suppl/GSM2562757_200069280004_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562757/suppl/GSM2562757_200069280004_R03C02_Red.idat.gz	485577
CHD7-60 whole blood CHD7 pathogenic genomic DNA	GSM2562758	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-60	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562758/suppl/GSM2562758_200069280004_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562758/suppl/GSM2562758_200069280004_R04C02_Red.idat.gz	485577
CHD7-61 whole blood CHD7 pathogenic genomic DNA	GSM2562759	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 1	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-61	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562759/suppl/GSM2562759_200069280082_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562759/suppl/GSM2562759_200069280082_R03C01_Red.idat.gz	485577
CHD7-62 whole blood CHD7 VUS genomic DNA	GSM2562760	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 29	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-62	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562760/suppl/GSM2562760_200069280082_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562760/suppl/GSM2562760_200069280082_R05C01_Red.idat.gz	485577
CHD7-63 whole blood CHD7 likely pathogenic genomic DNA	GSM2562761	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 1	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-63	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562761/suppl/GSM2562761_200069280082_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562761/suppl/GSM2562761_200069280082_R06C01_Red.idat.gz	485577
CHD7-64 whole blood CHD7 pathogenic genomic DNA	GSM2562762	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 2	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-64	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562762/suppl/GSM2562762_200069280082_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562762/suppl/GSM2562762_200069280082_R01C02_Red.idat.gz	485577
CHD7-65 whole blood CHD7 VUS genomic DNA	GSM2562763	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 52	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-65	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562763/suppl/GSM2562763_200069280082_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562763/suppl/GSM2562763_200069280082_R02C02_Red.idat.gz	485577
CHD7-66 whole blood CHD7 VUS genomic DNA	GSM2562764	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 10	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-66	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562764/suppl/GSM2562764_200069280082_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562764/suppl/GSM2562764_200069280082_R04C02_Red.idat.gz	485577
CHD7-67 whole blood CHD7 VUS genomic DNA	GSM2562765	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 2	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-67	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562765/suppl/GSM2562765_200069280082_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562765/suppl/GSM2562765_200069280082_R05C02_Red.idat.gz	485577
CHD7-68 whole blood CHD7 likely pathogenic genomic DNA	GSM2562766	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 7	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-68	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562766/suppl/GSM2562766_200069280013_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562766/suppl/GSM2562766_200069280013_R02C01_Red.idat.gz	485577
CHD7-69 whole blood CHD7 pathogenic genomic DNA	GSM2562767	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 4	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-69	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562767/suppl/GSM2562767_200069280013_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562767/suppl/GSM2562767_200069280013_R03C01_Red.idat.gz	485577
CHD7-70 whole blood CHD7 VUS genomic DNA	GSM2562768	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 26	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-70	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562768/suppl/GSM2562768_200069280013_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562768/suppl/GSM2562768_200069280013_R05C01_Red.idat.gz	485577
CHD7-71 whole blood CHD7 likely pathogenic genomic DNA	GSM2562769	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 4	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-71	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562769/suppl/GSM2562769_200069280013_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562769/suppl/GSM2562769_200069280013_R06C01_Red.idat.gz	485577
CHD7-72 whole blood CHD7 pathogenic genomic DNA	GSM2562770	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 46	sample type: Validation cohort	disease state: CHD7 variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	CHD7-72	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562770/suppl/GSM2562770_200069280013_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562770/suppl/GSM2562770_200069280013_R02C02_Red.idat.gz	485577
KMT2D-1 whole blood KMT2D LOF genomic DNA	GSM2562771	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 14	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-1	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562771/suppl/GSM2562771_9934987063_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562771/suppl/GSM2562771_9934987063_R03C01_Red.idat.gz	485577
KMT2D-2 whole blood KMT2D LOF genomic DNA	GSM2562772	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 1	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-2	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562772/suppl/GSM2562772_9934987063_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562772/suppl/GSM2562772_9934987063_R04C02_Red.idat.gz	485577
KMT2D-3 whole blood KMT2D LOF genomic DNA	GSM2562773	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 18	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-3	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562773/suppl/GSM2562773_9934987063_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562773/suppl/GSM2562773_9934987063_R01C02_Red.idat.gz	485577
KMT2D-4 whole blood KMT2D LOF genomic DNA	GSM2562774	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 16	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-4	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562774/suppl/GSM2562774_9934987063_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562774/suppl/GSM2562774_9934987063_R03C02_Red.idat.gz	485577
KMT2D-5 whole blood KMT2D LOF genomic DNA	GSM2562775	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 15	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-5	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562775/suppl/GSM2562775_9934987063_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562775/suppl/GSM2562775_9934987063_R06C02_Red.idat.gz	485577
KMT2D-6 whole blood KMT2D LOF genomic DNA	GSM2562776	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 11	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-6	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562776/suppl/GSM2562776_9934987132_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562776/suppl/GSM2562776_9934987132_R03C01_Red.idat.gz	485577
KMT2D-7 whole blood KMT2D LOF genomic DNA	GSM2562777	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 14	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-7	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562777/suppl/GSM2562777_9934987132_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562777/suppl/GSM2562777_9934987132_R04C01_Red.idat.gz	485577
KMT2D-8 whole blood KMT2D LOF genomic DNA	GSM2562778	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 20	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-8	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562778/suppl/GSM2562778_9934987132_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562778/suppl/GSM2562778_9934987132_R02C02_Red.idat.gz	485577
KMT2D-9 whole blood KMT2D LOF genomic DNA	GSM2562779	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 18	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-9	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562779/suppl/GSM2562779_9934987132_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562779/suppl/GSM2562779_9934987132_R03C02_Red.idat.gz	485577
KMT2D-10 whole blood KMT2D LOF genomic DNA	GSM2562780	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-10	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562780/suppl/GSM2562780_9934987132_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562780/suppl/GSM2562780_9934987132_R06C02_Red.idat.gz	485577
KMT2D-11 whole blood KMT2D LOF genomic DNA	GSM2562781	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16	sample type: KMT2D LOF discovery cohort	disease state: Kabuki	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-11	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562781/suppl/GSM2562781_9934987131_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562781/suppl/GSM2562781_9934987131_R03C01_Red.idat.gz	485577
KMT2D-12 whole blood KMT2D VUS genomic DNA	GSM2562782	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 7	sample type: KMT2D sequence variant	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-12	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562782/suppl/GSM2562782_9934987131_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562782/suppl/GSM2562782_9934987131_R04C01_Red.idat.gz	485577
KMT2D-13 whole blood KMT2D VUS genomic DNA	GSM2562783	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 5	sample type: KMT2D sequence variant	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-13	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562783/suppl/GSM2562783_9934987131_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562783/suppl/GSM2562783_9934987131_R01C01_Red.idat.gz	485577
KMT2D-14 whole blood KMT2D VUS genomic DNA	GSM2562784	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 15	sample type: KMT2D sequence variant	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-14	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562784/suppl/GSM2562784_9934987063_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562784/suppl/GSM2562784_9934987063_R04C01_Red.idat.gz	485577
KMT2D-15 whole blood KMT2D VUS genomic DNA	GSM2562785	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 14	sample type: KMT2D sequence variant	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-15	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562785/suppl/GSM2562785_200325530153_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562785/suppl/GSM2562785_200325530153_R01C02_Red.idat.gz	485577
KMT2D-16 whole blood KMT2D VUS genomic DNA	GSM2562786	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 17	sample type: KMT2D sequence variant	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-16	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562786/suppl/GSM2562786_9934987063_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562786/suppl/GSM2562786_9934987063_R02C01_Red.idat.gz	485577
KMT2D-17 whole blood KMT2D VUS genomic DNA	GSM2562787	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 9	sample type: KMT2D sequence variant	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-17	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562787/suppl/GSM2562787_9934987132_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562787/suppl/GSM2562787_9934987132_R02C01_Red.idat.gz	485577
KMT2D-18 whole blood KMT2D VUS genomic DNA	GSM2562788	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 16	sample type: KMT2D sequence variant	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-18	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562788/suppl/GSM2562788_9934987063_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562788/suppl/GSM2562788_9934987063_R06C01_Red.idat.gz	485577
KMT2D-19 whole blood KMT2D VUS genomic DNA	GSM2562789	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 8	sample type: KMT2D sequence variant	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-19	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562789/suppl/GSM2562789_9934987132_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562789/suppl/GSM2562789_9934987132_R06C01_Red.idat.gz	485577
KMT2D-20 whole blood KMT2D VUS genomic DNA	GSM2562790	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 10	sample type: KMT2D sequence variant	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-20	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562790/suppl/GSM2562790_9934987132_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562790/suppl/GSM2562790_9934987132_R05C02_Red.idat.gz	485577
KMT2D-21 whole blood KMT2D VUS genomic DNA	GSM2562791	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: KMT2D sequence variant	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-21	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562791/suppl/GSM2562791_9934987131_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562791/suppl/GSM2562791_9934987131_R02C01_Red.idat.gz	485577
KMT2D-22 whole blood KMT2D likely pathogenic genomic DNA	GSM2562792	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 5	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-22	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562792/suppl/GSM2562792_200069280057_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562792/suppl/GSM2562792_200069280057_R04C02_Red.idat.gz	485577
KMT2D-23 whole blood KMT2D VUS genomic DNA	GSM2562793	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 3	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-23	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562793/suppl/GSM2562793_200069280019_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562793/suppl/GSM2562793_200069280019_R02C01_Red.idat.gz	485577
KMT2D-24 whole blood KMT2D VUS genomic DNA	GSM2562794	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 21	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-24	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562794/suppl/GSM2562794_200069280019_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562794/suppl/GSM2562794_200069280019_R03C01_Red.idat.gz	485577
KMT2D-25 whole blood KMT2D likely pathogenic genomic DNA	GSM2562795	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 34	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-25	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562795/suppl/GSM2562795_200069280019_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562795/suppl/GSM2562795_200069280019_R06C01_Red.idat.gz	485577
KMT2D-26 whole blood KMT2D likely pathogenic genomic DNA	GSM2562796	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 30	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-26	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562796/suppl/GSM2562796_200069280070_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562796/suppl/GSM2562796_200069280070_R03C02_Red.idat.gz	485577
KMT2D-27 whole blood KMT2D VUS genomic DNA	GSM2562797	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 40	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-27	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562797/suppl/GSM2562797_200069280013_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562797/suppl/GSM2562797_200069280013_R01C02_Red.idat.gz	485577
KMT2D-28 whole blood KMT2D VUS genomic DNA	GSM2562798	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 9	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-28	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562798/suppl/GSM2562798_200069280013_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562798/suppl/GSM2562798_200069280013_R04C02_Red.idat.gz	485577
KMT2D-29 whole blood KMT2D pathogenic genomic DNA	GSM2562799	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 5	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-29	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562799/suppl/GSM2562799_200069280013_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562799/suppl/GSM2562799_200069280013_R05C02_Red.idat.gz	485577
KMT2D-30 whole blood KMT2D likely pathogenic genomic DNA	GSM2562800	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-30	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562800/suppl/GSM2562800_200069280101_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562800/suppl/GSM2562800_200069280101_R02C01_Red.idat.gz	485577
KMT2D-31 whole blood KMT2D VUS genomic DNA	GSM2562801	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 47	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-31	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562801/suppl/GSM2562801_200069280101_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562801/suppl/GSM2562801_200069280101_R05C01_Red.idat.gz	485577
KMT2D-32 whole blood KMT2D pathogenic genomic DNA	GSM2562802	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 51	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-32	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562802/suppl/GSM2562802_200069280101_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562802/suppl/GSM2562802_200069280101_R06C01_Red.idat.gz	485577
KMT2D-33 whole blood KMT2D likely pathogenic genomic DNA	GSM2562803	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 28	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-33	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562803/suppl/GSM2562803_200069280101_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562803/suppl/GSM2562803_200069280101_R01C02_Red.idat.gz	485577
KMT2D-34 whole blood KMT2D VUS genomic DNA	GSM2562804	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 25	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-34	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562804/suppl/GSM2562804_200069280101_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562804/suppl/GSM2562804_200069280101_R04C02_Red.idat.gz	485577
KMT2D-35 whole blood KMT2D VUS genomic DNA	GSM2562805	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 45	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-35	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562805/suppl/GSM2562805_200069280101_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562805/suppl/GSM2562805_200069280101_R05C02_Red.idat.gz	485577
KMT2D-36 whole blood KMT2D pathogenic genomic DNA	GSM2562806	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 27	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-36	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562806/suppl/GSM2562806_200069280057_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562806/suppl/GSM2562806_200069280057_R05C01_Red.idat.gz	485577
KMT2D-37 whole blood KMT2D VUS genomic DNA	GSM2562807	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 15	sample type: Validation cohort	disease state: KMT2D variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KMT2D-37	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562807/suppl/GSM2562807_200069280057_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562807/suppl/GSM2562807_200069280057_R02C02_Red.idat.gz	485577
KDM6A-1 whole blood KDM6A pathogenic genomic DNA	GSM2562808	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 12	sample type: Validation cohort	disease state: KDM6A variant	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	KDM6A-1	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562808/suppl/GSM2562808_200069280101_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562808/suppl/GSM2562808_200069280101_R03C01_Red.idat.gz	485577
control-1 whole blood Control genomic DNA	GSM2562809	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 11	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-1	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562809/suppl/GSM2562809_9376525031_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562809/suppl/GSM2562809_9376525031_R01C01_Red.idat.gz	485577
control-2 whole blood Control genomic DNA	GSM2562810	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 4	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-2	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562810/suppl/GSM2562810_9376525031_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562810/suppl/GSM2562810_9376525031_R06C01_Red.idat.gz	485577
control-3 whole blood Control genomic DNA	GSM2562811	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-3	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562811/suppl/GSM2562811_9376525031_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562811/suppl/GSM2562811_9376525031_R03C02_Red.idat.gz	485577
control-4 whole blood Control genomic DNA	GSM2562812	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 5	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-4	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562812/suppl/GSM2562812_9376525031_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562812/suppl/GSM2562812_9376525031_R05C02_Red.idat.gz	485577
control-5 whole blood Control genomic DNA	GSM2562813	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 16	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-5	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562813/suppl/GSM2562813_9376525009_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562813/suppl/GSM2562813_9376525009_R01C01_Red.idat.gz	485577
control-6 whole blood Control genomic DNA	GSM2562814	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-6	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562814/suppl/GSM2562814_9376525009_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562814/suppl/GSM2562814_9376525009_R02C01_Red.idat.gz	485577
control-7 whole blood Control genomic DNA	GSM2562815	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 12	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-7	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562815/suppl/GSM2562815_9376525009_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562815/suppl/GSM2562815_9376525009_R04C01_Red.idat.gz	485577
control-8 whole blood Control genomic DNA	GSM2562816	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 6	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-8	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562816/suppl/GSM2562816_9376525009_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562816/suppl/GSM2562816_9376525009_R01C02_Red.idat.gz	485577
control-9 whole blood Control genomic DNA	GSM2562817	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 7	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-9	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562817/suppl/GSM2562817_9376525009_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562817/suppl/GSM2562817_9376525009_R02C02_Red.idat.gz	485577
control-10 whole blood Control genomic DNA	GSM2562818	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 7	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-10	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562818/suppl/GSM2562818_9376525009_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562818/suppl/GSM2562818_9376525009_R03C02_Red.idat.gz	485577
control-11 whole blood Control genomic DNA	GSM2562819	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 9	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-11	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562819/suppl/GSM2562819_9376525009_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562819/suppl/GSM2562819_9376525009_R04C02_Red.idat.gz	485577
control-12 whole blood Control genomic DNA	GSM2562820	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-12	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562820/suppl/GSM2562820_9376525033_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562820/suppl/GSM2562820_9376525033_R01C01_Red.idat.gz	485577
control-13 whole blood Control genomic DNA	GSM2562821	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-13	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562821/suppl/GSM2562821_9376525033_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562821/suppl/GSM2562821_9376525033_R04C01_Red.idat.gz	485577
control-14 whole blood Control genomic DNA	GSM2562822	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 11	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-14	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562822/suppl/GSM2562822_9376525033_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562822/suppl/GSM2562822_9376525033_R06C01_Red.idat.gz	485577
control-15 whole blood Control genomic DNA	GSM2562823	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 4	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-15	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562823/suppl/GSM2562823_9376525033_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562823/suppl/GSM2562823_9376525033_R02C02_Red.idat.gz	485577
control-16 whole blood Control genomic DNA	GSM2562824	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 6.25	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-16	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562824/suppl/GSM2562824_9376525033_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562824/suppl/GSM2562824_9376525033_R05C02_Red.idat.gz	485577
control-17 whole blood Control genomic DNA	GSM2562825	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 5	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-17	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562825/suppl/GSM2562825_9376525033_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562825/suppl/GSM2562825_9376525033_R06C02_Red.idat.gz	485577
control-18 whole blood Control genomic DNA	GSM2562826	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-18	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562826/suppl/GSM2562826_9376525027_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562826/suppl/GSM2562826_9376525027_R02C01_Red.idat.gz	485577
control-19 whole blood Control genomic DNA	GSM2562827	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 4	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-19	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562827/suppl/GSM2562827_9376525027_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562827/suppl/GSM2562827_9376525027_R04C01_Red.idat.gz	485577
control-20 whole blood Control genomic DNA	GSM2562828	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 5	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-20	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562828/suppl/GSM2562828_9376525027_R06C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562828/suppl/GSM2562828_9376525027_R06C01_Red.idat.gz	485577
control-21 whole blood Control genomic DNA	GSM2562829	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 2	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-21	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562829/suppl/GSM2562829_9376525027_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562829/suppl/GSM2562829_9376525027_R04C02_Red.idat.gz	485577
control-22 whole blood Control genomic DNA	GSM2562830	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 10	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-22	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562830/suppl/GSM2562830_9376525052_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562830/suppl/GSM2562830_9376525052_R02C01_Red.idat.gz	485577
control-23 whole blood Control genomic DNA	GSM2562831	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 8	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-23	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562831/suppl/GSM2562831_9376525052_R03C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562831/suppl/GSM2562831_9376525052_R03C01_Red.idat.gz	485577
control-24 whole blood Control genomic DNA	GSM2562832	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 11	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-24	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562832/suppl/GSM2562832_9376525052_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562832/suppl/GSM2562832_9376525052_R01C02_Red.idat.gz	485577
control-25 whole blood Control genomic DNA	GSM2562833	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-25	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562833/suppl/GSM2562833_9376525052_R02C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562833/suppl/GSM2562833_9376525052_R02C02_Red.idat.gz	485577
control-26 whole blood Control genomic DNA	GSM2562834	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 14	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-26	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562834/suppl/GSM2562834_9376525052_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562834/suppl/GSM2562834_9376525052_R04C02_Red.idat.gz	485577
control-27 whole blood Control genomic DNA	GSM2562835	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 3	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-27	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562835/suppl/GSM2562835_9376525052_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562835/suppl/GSM2562835_9376525052_R06C02_Red.idat.gz	485577
control-28 whole blood Control genomic DNA	GSM2562836	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 10	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-28	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562836/suppl/GSM2562836_9376525032_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562836/suppl/GSM2562836_9376525032_R02C01_Red.idat.gz	485577
control-29 whole blood Control genomic DNA	GSM2562837	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 7	sample type: Control for CHD7 LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-29	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562837/suppl/GSM2562837_9376525032_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562837/suppl/GSM2562837_9376525032_R05C02_Red.idat.gz	485577
control-30 whole blood Control genomic DNA	GSM2562838	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-30	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562838/suppl/GSM2562838_9934987132_R05C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562838/suppl/GSM2562838_9934987132_R05C01_Red.idat.gz	485577
control-31 whole blood Control genomic DNA	GSM2562839	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-31	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562839/suppl/GSM2562839_9934987132_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562839/suppl/GSM2562839_9934987132_R01C02_Red.idat.gz	485577
control-32 whole blood Control genomic DNA	GSM2562840	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 11	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-32	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562840/suppl/GSM2562840_9934987132_R04C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562840/suppl/GSM2562840_9934987132_R04C02_Red.idat.gz	485577
control-33 whole blood Control genomic DNA	GSM2562841	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-33	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562841/suppl/GSM2562841_9934987132_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562841/suppl/GSM2562841_9934987132_R01C01_Red.idat.gz	485577
control-34 whole blood Control genomic DNA	GSM2562842	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 16	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-34	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562842/suppl/GSM2562842_9934987063_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562842/suppl/GSM2562842_9934987063_R01C01_Red.idat.gz	485577
control-35 whole blood Control genomic DNA	GSM2562843	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 5.5	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-35	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562843/suppl/GSM2562843_9934987128_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562843/suppl/GSM2562843_9934987128_R02C01_Red.idat.gz	485577
control-36 whole blood Control genomic DNA	GSM2562844	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 7	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-36	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562844/suppl/GSM2562844_9934987128_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562844/suppl/GSM2562844_9934987128_R01C02_Red.idat.gz	485577
control-37 whole blood Control genomic DNA	GSM2562845	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 7	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-37	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562845/suppl/GSM2562845_9934987128_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562845/suppl/GSM2562845_9934987128_R03C02_Red.idat.gz	485577
control-38 whole blood Control genomic DNA	GSM2562846	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 8	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-38	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562846/suppl/GSM2562846_9934987146_R02C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562846/suppl/GSM2562846_9934987146_R02C01_Red.idat.gz	485577
control-39 whole blood Control genomic DNA	GSM2562847	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 9.5	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-39	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562847/suppl/GSM2562847_9934987146_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562847/suppl/GSM2562847_9934987146_R04C01_Red.idat.gz	485577
control-40 whole blood Control genomic DNA	GSM2562848	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 9	sample type: Control for KMT2D LOF discovery cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-40	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562848/suppl/GSM2562848_9934987146_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562848/suppl/GSM2562848_9934987146_R01C02_Red.idat.gz	485577
control-41 whole blood Control genomic DNA	GSM2562849	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 16	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-41	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562849/suppl/GSM2562849_200069280110_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562849/suppl/GSM2562849_200069280110_R01C01_Red.idat.gz	485577
control-42 whole blood Control genomic DNA	GSM2562850	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 11	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-42	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562850/suppl/GSM2562850_200069280110_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562850/suppl/GSM2562850_200069280110_R04C01_Red.idat.gz	485577
control-43 whole blood Control genomic DNA	GSM2562851	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 15	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-43	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562851/suppl/GSM2562851_200069280110_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562851/suppl/GSM2562851_200069280110_R03C02_Red.idat.gz	485577
control-44 whole blood Control genomic DNA	GSM2562852	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 12	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-44	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562852/suppl/GSM2562852_200069280110_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562852/suppl/GSM2562852_200069280110_R06C02_Red.idat.gz	485577
control-45 whole blood Control genomic DNA	GSM2562853	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 17	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-45	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562853/suppl/GSM2562853_200069280056_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562853/suppl/GSM2562853_200069280056_R01C01_Red.idat.gz	485577
control-46 whole blood Control genomic DNA	GSM2562854	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 15	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-46	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562854/suppl/GSM2562854_200069280056_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562854/suppl/GSM2562854_200069280056_R04C01_Red.idat.gz	485577
control-47 whole blood Control genomic DNA	GSM2562855	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 12	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-47	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562855/suppl/GSM2562855_200069280056_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562855/suppl/GSM2562855_200069280056_R03C02_Red.idat.gz	485577
control-48 whole blood Control genomic DNA	GSM2562856	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-48	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562856/suppl/GSM2562856_200069280056_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562856/suppl/GSM2562856_200069280056_R06C02_Red.idat.gz	485577
control-49 whole blood Control genomic DNA	GSM2562857	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 18	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-49	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562857/suppl/GSM2562857_200053730212_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562857/suppl/GSM2562857_200053730212_R01C01_Red.idat.gz	485577
control-50 whole blood Control genomic DNA	GSM2562858	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 18	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-50	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562858/suppl/GSM2562858_200053730212_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562858/suppl/GSM2562858_200053730212_R04C01_Red.idat.gz	485577
control-51 whole blood Control genomic DNA	GSM2562859	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 6	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-51	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562859/suppl/GSM2562859_200053730212_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562859/suppl/GSM2562859_200053730212_R03C02_Red.idat.gz	485577
control-52 whole blood Control genomic DNA	GSM2562860	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 11	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-52	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562860/suppl/GSM2562860_200053730212_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562860/suppl/GSM2562860_200053730212_R06C02_Red.idat.gz	485577
control-53 whole blood Control genomic DNA	GSM2562861	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 18	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-53	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562861/suppl/GSM2562861_200069280102_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562861/suppl/GSM2562861_200069280102_R01C01_Red.idat.gz	485577
control-54 whole blood Control genomic DNA	GSM2562862	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 19	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-54	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562862/suppl/GSM2562862_200069280102_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562862/suppl/GSM2562862_200069280102_R04C01_Red.idat.gz	485577
control-55 whole blood Control genomic DNA	GSM2562863	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 14	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-55	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562863/suppl/GSM2562863_200069280102_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562863/suppl/GSM2562863_200069280102_R03C02_Red.idat.gz	485577
control-56 whole blood Control genomic DNA	GSM2562864	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-56	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562864/suppl/GSM2562864_200069280102_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562864/suppl/GSM2562864_200069280102_R06C02_Red.idat.gz	485577
control-57 whole blood Control genomic DNA	GSM2562865	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 13	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-57	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562865/suppl/GSM2562865_200053730213_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562865/suppl/GSM2562865_200053730213_R01C01_Red.idat.gz	485577
control-58 whole blood Control genomic DNA	GSM2562866	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-58	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562866/suppl/GSM2562866_200053730213_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562866/suppl/GSM2562866_200053730213_R04C01_Red.idat.gz	485577
control-59 whole blood Control genomic DNA	GSM2562867	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-59	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562867/suppl/GSM2562867_200053730213_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562867/suppl/GSM2562867_200053730213_R03C02_Red.idat.gz	485577
control-60 whole blood Control genomic DNA	GSM2562868	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 11.5	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-60	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562868/suppl/GSM2562868_200053730213_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562868/suppl/GSM2562868_200053730213_R06C02_Red.idat.gz	485577
control-61 whole blood Control genomic DNA	GSM2562869	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-61	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562869/suppl/GSM2562869_200069280068_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562869/suppl/GSM2562869_200069280068_R01C01_Red.idat.gz	485577
control-62 whole blood Control genomic DNA	GSM2562870	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-62	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562870/suppl/GSM2562870_200069280068_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562870/suppl/GSM2562870_200069280068_R04C01_Red.idat.gz	485577
control-63 whole blood Control genomic DNA	GSM2562871	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 15	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-63	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562871/suppl/GSM2562871_200069280068_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562871/suppl/GSM2562871_200069280068_R03C02_Red.idat.gz	485577
control-64 whole blood Control genomic DNA	GSM2562872	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 7	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-64	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562872/suppl/GSM2562872_200069280068_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562872/suppl/GSM2562872_200069280068_R06C02_Red.idat.gz	485577
control-65 whole blood Control genomic DNA	GSM2562873	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16.5	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-65	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562873/suppl/GSM2562873_200053730211_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562873/suppl/GSM2562873_200053730211_R01C01_Red.idat.gz	485577
control-66 whole blood Control genomic DNA	GSM2562874	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 17	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-66	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562874/suppl/GSM2562874_200053730211_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562874/suppl/GSM2562874_200053730211_R04C01_Red.idat.gz	485577
control-67 whole blood Control genomic DNA	GSM2562875	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 17	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-67	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562875/suppl/GSM2562875_200053730211_R01C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562875/suppl/GSM2562875_200053730211_R01C02_Red.idat.gz	485577
control-68 whole blood Control genomic DNA	GSM2562876	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 15.5	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-68	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562876/suppl/GSM2562876_200053730211_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562876/suppl/GSM2562876_200053730211_R03C02_Red.idat.gz	485577
control-69 whole blood Control genomic DNA	GSM2562877	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 6	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-69	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562877/suppl/GSM2562877_200053730211_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562877/suppl/GSM2562877_200053730211_R06C02_Red.idat.gz	485577
control-70 whole blood Control genomic DNA	GSM2562878	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13.5	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-70	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562878/suppl/GSM2562878_200053730149_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562878/suppl/GSM2562878_200053730149_R01C01_Red.idat.gz	485577
control-71 whole blood Control genomic DNA	GSM2562879	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-71	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562879/suppl/GSM2562879_200053730149_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562879/suppl/GSM2562879_200053730149_R03C02_Red.idat.gz	485577
control-72 whole blood Control genomic DNA	GSM2562880	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 14	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-72	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562880/suppl/GSM2562880_200053730149_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562880/suppl/GSM2562880_200053730149_R06C02_Red.idat.gz	485577
control-73 whole blood Control genomic DNA	GSM2562881	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 18	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-73	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562881/suppl/GSM2562881_200069280111_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562881/suppl/GSM2562881_200069280111_R01C01_Red.idat.gz	485577
control-74 whole blood Control genomic DNA	GSM2562882	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): -	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-74	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562882/suppl/GSM2562882_200069280111_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562882/suppl/GSM2562882_200069280111_R04C01_Red.idat.gz	485577
control-75 whole blood Control genomic DNA	GSM2562883	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 16	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-75	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562883/suppl/GSM2562883_200069280111_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562883/suppl/GSM2562883_200069280111_R03C02_Red.idat.gz	485577
control-76 whole blood Control genomic DNA	GSM2562884	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 10	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-76	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562884/suppl/GSM2562884_200069280111_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562884/suppl/GSM2562884_200069280111_R06C02_Red.idat.gz	485577
control-77 whole blood Control genomic DNA	GSM2562885	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 15	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-77	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562885/suppl/GSM2562885_200053730181_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562885/suppl/GSM2562885_200053730181_R01C01_Red.idat.gz	485577
control-78 whole blood Control genomic DNA	GSM2562886	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 3	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-78	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562886/suppl/GSM2562886_200053730181_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562886/suppl/GSM2562886_200053730181_R04C01_Red.idat.gz	485577
control-79 whole blood Control genomic DNA	GSM2562887	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 6	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-79	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562887/suppl/GSM2562887_200053730181_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562887/suppl/GSM2562887_200053730181_R06C02_Red.idat.gz	485577
control-80 whole blood Control genomic DNA	GSM2562888	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): -	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-80	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562888/suppl/GSM2562888_200069280005_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562888/suppl/GSM2562888_200069280005_R01C01_Red.idat.gz	485577
control-81 whole blood Control genomic DNA	GSM2562889	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 18	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-81	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562889/suppl/GSM2562889_200069280005_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562889/suppl/GSM2562889_200069280005_R04C01_Red.idat.gz	485577
control-82 whole blood Control genomic DNA	GSM2562890	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 7	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-82	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562890/suppl/GSM2562890_200069280005_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562890/suppl/GSM2562890_200069280005_R03C02_Red.idat.gz	485577
control-83 whole blood Control genomic DNA	GSM2562891	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 19	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-83	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562891/suppl/GSM2562891_200069280005_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562891/suppl/GSM2562891_200069280005_R06C02_Red.idat.gz	485577
control-84 whole blood Control genomic DNA	GSM2562892	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 14	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-84	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562892/suppl/GSM2562892_200069280100_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562892/suppl/GSM2562892_200069280100_R01C01_Red.idat.gz	485577
control-85 whole blood Control genomic DNA	GSM2562893	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 15	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-85	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562893/suppl/GSM2562893_200069280100_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562893/suppl/GSM2562893_200069280100_R04C01_Red.idat.gz	485577
control-86 whole blood Control genomic DNA	GSM2562894	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 19	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-86	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562894/suppl/GSM2562894_200069280100_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562894/suppl/GSM2562894_200069280100_R06C02_Red.idat.gz	485577
control-87 whole blood Control genomic DNA	GSM2562895	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 8	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-87	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562895/suppl/GSM2562895_200069280070_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562895/suppl/GSM2562895_200069280070_R01C01_Red.idat.gz	485577
control-88 whole blood Control genomic DNA	GSM2562896	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 15	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-88	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562896/suppl/GSM2562896_200069280070_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562896/suppl/GSM2562896_200069280070_R04C01_Red.idat.gz	485577
control-89 whole blood Control genomic DNA	GSM2562897	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-89	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562897/suppl/GSM2562897_200069280070_R05C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562897/suppl/GSM2562897_200069280070_R05C02_Red.idat.gz	485577
control-90 whole blood Control genomic DNA	GSM2562898	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 4	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-90	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562898/suppl/GSM2562898_200069280030_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562898/suppl/GSM2562898_200069280030_R01C01_Red.idat.gz	485577
control-91 whole blood Control genomic DNA	GSM2562899	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 19	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-91	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562899/suppl/GSM2562899_200069280030_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562899/suppl/GSM2562899_200069280030_R04C01_Red.idat.gz	485577
control-92 whole blood Control genomic DNA	GSM2562900	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 18	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-92	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562900/suppl/GSM2562900_200069280030_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562900/suppl/GSM2562900_200069280030_R06C02_Red.idat.gz	485577
control-93 whole blood Control genomic DNA	GSM2562901	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 14	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-93	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562901/suppl/GSM2562901_200053730139_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562901/suppl/GSM2562901_200053730139_R01C01_Red.idat.gz	485577
control-94 whole blood Control genomic DNA	GSM2562902	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 17	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-94	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562902/suppl/GSM2562902_200053730139_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562902/suppl/GSM2562902_200053730139_R04C01_Red.idat.gz	485577
control-95 whole blood Control genomic DNA	GSM2562903	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 14	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-95	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562903/suppl/GSM2562903_200053730139_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562903/suppl/GSM2562903_200053730139_R03C02_Red.idat.gz	485577
control-96 whole blood Control genomic DNA	GSM2562904	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 13	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-96	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562904/suppl/GSM2562904_200053730139_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562904/suppl/GSM2562904_200053730139_R06C02_Red.idat.gz	485577
control-97 whole blood Control genomic DNA	GSM2562905	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 19	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-97	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562905/suppl/GSM2562905_200069280004_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562905/suppl/GSM2562905_200069280004_R01C01_Red.idat.gz	485577
control-98 whole blood Control genomic DNA	GSM2562906	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 18	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-98	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562906/suppl/GSM2562906_200069280004_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562906/suppl/GSM2562906_200069280004_R04C01_Red.idat.gz	485577
control-99 whole blood Control genomic DNA	GSM2562907	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16.8	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-99	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562907/suppl/GSM2562907_200069280004_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562907/suppl/GSM2562907_200069280004_R06C02_Red.idat.gz	485577
control-100 whole blood Control genomic DNA	GSM2562908	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 17	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-100	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562908/suppl/GSM2562908_200069280082_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562908/suppl/GSM2562908_200069280082_R01C01_Red.idat.gz	485577
control-101 whole blood Control genomic DNA	GSM2562909	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 11	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-101	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562909/suppl/GSM2562909_200069280082_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562909/suppl/GSM2562909_200069280082_R04C01_Red.idat.gz	485577
control-102 whole blood Control genomic DNA	GSM2562910	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 14	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-102	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562910/suppl/GSM2562910_200069280082_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562910/suppl/GSM2562910_200069280082_R03C02_Red.idat.gz	485577
control-103 whole blood Control genomic DNA	GSM2562911	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 19	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-103	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562911/suppl/GSM2562911_200069280082_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562911/suppl/GSM2562911_200069280082_R06C02_Red.idat.gz	485577
control-104 whole blood Control genomic DNA	GSM2562912	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 14	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-104	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562912/suppl/GSM2562912_200069280013_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562912/suppl/GSM2562912_200069280013_R01C01_Red.idat.gz	485577
control-105 whole blood Control genomic DNA	GSM2562913	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 17	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-105	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562913/suppl/GSM2562913_200069280013_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562913/suppl/GSM2562913_200069280013_R04C01_Red.idat.gz	485577
control-106 whole blood Control genomic DNA	GSM2562914	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 12	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-106	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562914/suppl/GSM2562914_200069280013_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562914/suppl/GSM2562914_200069280013_R03C02_Red.idat.gz	485577
control-107 whole blood Control genomic DNA	GSM2562915	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 10	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-107	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562915/suppl/GSM2562915_200069280013_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562915/suppl/GSM2562915_200069280013_R06C02_Red.idat.gz	485577
control-108 whole blood Control genomic DNA	GSM2562916	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 19	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-108	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562916/suppl/GSM2562916_200069280101_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562916/suppl/GSM2562916_200069280101_R01C01_Red.idat.gz	485577
control-109 whole blood Control genomic DNA	GSM2562917	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 19	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-109	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562917/suppl/GSM2562917_200069280101_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562917/suppl/GSM2562917_200069280101_R04C01_Red.idat.gz	485577
control-110 whole blood Control genomic DNA	GSM2562918	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-110	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562918/suppl/GSM2562918_200069280101_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562918/suppl/GSM2562918_200069280101_R03C02_Red.idat.gz	485577
control-111 whole blood Control genomic DNA	GSM2562919	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 18	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-111	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562919/suppl/GSM2562919_200069280101_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562919/suppl/GSM2562919_200069280101_R06C02_Red.idat.gz	485577
control-112 whole blood Control genomic DNA	GSM2562922	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 13	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-112	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562922/suppl/GSM2562922_200069280057_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562922/suppl/GSM2562922_200069280057_R01C01_Red.idat.gz	485577
control-113 whole blood Control genomic DNA	GSM2562923	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 17	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-113	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562923/suppl/GSM2562923_200069280057_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562923/suppl/GSM2562923_200069280057_R04C01_Red.idat.gz	485577
control-114 whole blood Control genomic DNA	GSM2562924	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 18	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-114	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562924/suppl/GSM2562924_200069280057_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562924/suppl/GSM2562924_200069280057_R03C02_Red.idat.gz	485577
control-115 whole blood Control genomic DNA	GSM2562925	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 14	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-115	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562925/suppl/GSM2562925_200069280057_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562925/suppl/GSM2562925_200069280057_R06C02_Red.idat.gz	485577
control-116 whole blood Control genomic DNA	GSM2562926	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 19	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-116	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562926/suppl/GSM2562926_200069280019_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562926/suppl/GSM2562926_200069280019_R01C01_Red.idat.gz	485577
control-117 whole blood Control genomic DNA	GSM2562927	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: female	age (years): 8	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-117	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562927/suppl/GSM2562927_200069280019_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562927/suppl/GSM2562927_200069280019_R04C01_Red.idat.gz	485577
control-118 whole blood Control genomic DNA	GSM2562928	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 16	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-118	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562928/suppl/GSM2562928_200069280019_R03C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562928/suppl/GSM2562928_200069280019_R03C02_Red.idat.gz	485577
control-119 whole blood Control genomic DNA	GSM2562929	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 11	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-119	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562929/suppl/GSM2562929_200069280019_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562929/suppl/GSM2562929_200069280019_R06C02_Red.idat.gz	485577
control-120 whole blood Control genomic DNA	GSM2562930	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 14	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-120	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562930/suppl/GSM2562930_200053730148_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562930/suppl/GSM2562930_200053730148_R01C01_Red.idat.gz	485577
control-121 whole blood Control genomic DNA	GSM2562931	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 7	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-121	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562931/suppl/GSM2562931_200053730148_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562931/suppl/GSM2562931_200053730148_R04C01_Red.idat.gz	485577
control-122 whole blood Control genomic DNA	GSM2562932	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 12	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-122	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562932/suppl/GSM2562932_200053730148_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562932/suppl/GSM2562932_200053730148_R06C02_Red.idat.gz	485577
control-123 whole blood Control genomic DNA	GSM2562933	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 10	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-123	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562933/suppl/GSM2562933_200069280109_R01C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562933/suppl/GSM2562933_200069280109_R01C01_Red.idat.gz	485577
control-124 whole blood Control genomic DNA	GSM2562934	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 11	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-124	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562934/suppl/GSM2562934_200069280109_R04C01_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562934/suppl/GSM2562934_200069280109_R04C01_Red.idat.gz	485577
control-125 whole blood Control genomic DNA	GSM2562935	Public on May 03 2017	Apr 03 2017	May 04 2017	genomic	1	whole blood genomic DNA	Homo sapiens	gender: male	age (years): 11	sample type: Control for validation cohort	disease state: Control	tissue: whole blood	genomic DNA	All genomic DNA were extracted from whole blood using standard procedures. One microgram of genomic DNA was sodium bisulfite modified using the Qiagen EZ DNA Methylation kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Modified genomic DNA was then processed and analyzed on the Infinium HumanMethylation450 BeadChip from Illumina according to the manufacturer’s protocol.	Cy5 and Cy3	Standard Illumina Protocol	9606	Bisulphite converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 Beadchip using standard Illumina protocol	Using an Illumina HiScan	control-125	Background subtraction and normalization to internal array controls were performed on raw intensity data using Illumina GenomeStudio v2011.1 Methylation Module 1.9 software. Probes containing single nucleotide polymorphisms (SNPs), cross-reactive probes with sequences aligned to multiple positions with ≥ 90% identity, and non-specific chromosome probes were removed.	GPL13534	Rosanna,,Weksberg	Weksberg Lab	Genetics and Genome Biology	The Hospital for Sick Children	555 University Ave.	Toronto	Ontario	M5G 2L3	Canada	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562935/suppl/GSM2562935_200069280109_R06C02_Grn.idat.gz	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2562nnn/GSM2562935/suppl/GSM2562935_200069280109_R06C02_Red.idat.gz	485577
